AI assistant
Sending…
Actinium Pharmaceuticals, Inc. — Director's Dealing 2018
Mar 19, 2018
34570_dirs_2018-03-19_0829c50e-2f7f-4a13-9072-3fb82491194d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2018-03-06
Reporting Person: Berger Mark Stanley (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-06 | Common Stock | J | 14000 | $0.5 | Acquired | 19000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-06 | Series A Warrants | $0.60 | J | 3500 | Acquired | 2019-03-06 | Common Stock (3500) | Direct |
| 2018-03-06 | Series B Warrants | $0.70 | J | 10500 | Acquired | 2020-09-06 | Common Stock (10500) | Direct |
More from Actinium Pharmaceuticals, Inc.
Regulatory Filings
2026
May 29
Annual Report
2026
Mar 30
Regulatory Filings
2026
Mar 26
Regulatory Filings
2026
Feb 13
Declaration of Voting Results & Voting Rights Announcements
2025
Nov 26
Interim / Quarterly Report
2025
Nov 14
Annual Report
2025
Nov 5
Proxy Solicitation & Information Statement
2025
Nov 5
Director's Dealing
2025
Aug 20
Interim / Quarterly Report
2025
Aug 8